05.07.14
OncoSil Medical Limited has added three executives to its management team in an effort to commence a global registration study for its core product, a localized radition therapy for pancreatic cancer treatment. The firm has appointed Natalie Ruffles vice president of Clinical Research; Lawrence Gozlan as independent non-executive company director; and Peter Casey as joint company secretary.
“We are delighted to secure the appointment of Ms. Ruffles as vice president of clinical research," OncoSil Medical CEO Dr. Neil Frazer said. "This represents a key hire for the company and Ms. Ruffles will play a pivotal role in recruiting for the clinical trial of OncoSil and ensuring the highest amount of integrity in the study data. Her experience in running clinical trials for medical devices will be invaluable as we progress the trial process for OncoSil.”
Gozlan is a highly experienced biotechnology industry professional, according to OncoSil, with particular expertise in investment management and corporate advice in the life sciences sector. He is the founder and chief investment officer of specialized global life sciences fund Scientia Capital, an entity that manages investments for high-net worth individuals, family offices and institutional investors seeking exposure to the biotechnology industry.
Before establishing Scientia Capital, Gozlan managed Australia's largest biotechnology investment portfolio as Queensland Investment Corporation's (QIC) institutional biotechnology analyst. QIC is a funds manager with more than $60 billion (in Australian dollars) under management. He also held roles with Foster Stockbroking as the senior biotechnology analyst in the equities team and Deloitte, where he provided corporate advice for life sciences companies.
Gozlan currently is a director of Prana Biotechnology, Ausbiotech Ltd. and various other private healthcare companies. He holds a bachelor of science with honours in microbiology and immunology from the University of Melbourne (in Australia).
"On behalf of the board of directors it is with great pleasure that we welcome the appointment of Lawrence Gozlan as non-exec director. His experience and track record as a biotech investment manager will be invaluable to the company, and we are confident his input and contribution will further strengthen the board," OncoSil Medical Chairman Martin Rogers said.
Casey has significant financial experience and extensive knowledge of the (company) secretarial field. He's worked for a private investment group as a senior finance executive for more than 20 years. His responsibilities have included financial reporting, governance and compliance, in addition to serving as company secretary throughout that period.
Casey is a chartered accountant and a member of the Australian Institute of Company Directors. He has a Bachelor of Arts degree, majoring in accounting from Macquarie University.
Casey will perform his duties as OncoSil’s joint company secretary in tandem with Nicholas Falzon.
“We are delighted to welcome Mr. Casey to the company," Frazer said. "He will play a significant role in ensuring our reporting, governance and compliance functions are carried out to ‘best practice’ standard, and we look forward to benefiting from his strong depth of expertise and experience in this area of our operations.”
OncoSil Medical develops radiation therapeutic delivery methods for tumors.
Ruffles has a decade of experience running clinical trials for medical devices and pharmaceutical investigational products.She will manage all the company's clinical studies, and provide guidance on clinical strategy for new trials. Her role will involve the management of all operational and logistical tasks related the company’s clinical study development to ensure the efficient execution of trials within established budgets and timelines, and also to ensure all activities are undertaken in compliance with the appropriate regulations. She also will coordinate patient recruitment efforts, study site selection and execute quality trials.
Ruffles most recently worked for Medtronic Inc. managing its clinical programmes in Australia/New Zealand. Prior to that, she worked for a number of global contract research organizations in monitoring, project management and business development roles. Ruffles has a BSc (Biomedical Science) and an MSc (Science Management) from the University of Technology in Sydney, Australia.
Ruffles most recently worked for Medtronic Inc. managing its clinical programmes in Australia/New Zealand. Prior to that, she worked for a number of global contract research organizations in monitoring, project management and business development roles. Ruffles has a BSc (Biomedical Science) and an MSc (Science Management) from the University of Technology in Sydney, Australia.
“We are delighted to secure the appointment of Ms. Ruffles as vice president of clinical research," OncoSil Medical CEO Dr. Neil Frazer said. "This represents a key hire for the company and Ms. Ruffles will play a pivotal role in recruiting for the clinical trial of OncoSil and ensuring the highest amount of integrity in the study data. Her experience in running clinical trials for medical devices will be invaluable as we progress the trial process for OncoSil.”
Gozlan is a highly experienced biotechnology industry professional, according to OncoSil, with particular expertise in investment management and corporate advice in the life sciences sector. He is the founder and chief investment officer of specialized global life sciences fund Scientia Capital, an entity that manages investments for high-net worth individuals, family offices and institutional investors seeking exposure to the biotechnology industry.
Before establishing Scientia Capital, Gozlan managed Australia's largest biotechnology investment portfolio as Queensland Investment Corporation's (QIC) institutional biotechnology analyst. QIC is a funds manager with more than $60 billion (in Australian dollars) under management. He also held roles with Foster Stockbroking as the senior biotechnology analyst in the equities team and Deloitte, where he provided corporate advice for life sciences companies.
Gozlan currently is a director of Prana Biotechnology, Ausbiotech Ltd. and various other private healthcare companies. He holds a bachelor of science with honours in microbiology and immunology from the University of Melbourne (in Australia).
"On behalf of the board of directors it is with great pleasure that we welcome the appointment of Lawrence Gozlan as non-exec director. His experience and track record as a biotech investment manager will be invaluable to the company, and we are confident his input and contribution will further strengthen the board," OncoSil Medical Chairman Martin Rogers said.
Casey has significant financial experience and extensive knowledge of the (company) secretarial field. He's worked for a private investment group as a senior finance executive for more than 20 years. His responsibilities have included financial reporting, governance and compliance, in addition to serving as company secretary throughout that period.
Casey is a chartered accountant and a member of the Australian Institute of Company Directors. He has a Bachelor of Arts degree, majoring in accounting from Macquarie University.
Casey will perform his duties as OncoSil’s joint company secretary in tandem with Nicholas Falzon.
“We are delighted to welcome Mr. Casey to the company," Frazer said. "He will play a significant role in ensuring our reporting, governance and compliance functions are carried out to ‘best practice’ standard, and we look forward to benefiting from his strong depth of expertise and experience in this area of our operations.”
OncoSil Medical develops radiation therapeutic delivery methods for tumors.